FHTX
What one share of Foghorn Therapeutics holds
Pharmaceutical Preparations
Foghorn is a clinical stage, precision therapeutics biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system, an untapped opportunity for therapeutic intervention in oncology and with potential in a wide spectrum of other diseases, including immunology and inflammation.
Foghorn Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.55 |
|---|---|
| Profit | −$0.97 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.27 |
| Cash and investments | $1.16 |
| Book value | −$1.38 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$12.20 | $0.23 | −$11.28 | — | — |
| 2020 | $0.04 | −$6.23 | $1.46 | −$4.30 | — | — |
| 2021 | $0.04 | −$2.73 | $0.09 | −$1.44 | — | — |
| 2022 | $0.46 | −$2.62 | $0.03 | $4.63 | — | $0.00 |
| 2023 | $0.81 | −$2.34 | $0.03 | −$2.84 | — | −$1.83 |
| 2024 | $0.41 | −$1.58 | $0.02 | −$1.85 | — | −$0.82 |
| 2025 | $0.49 | −$1.18 | $0.00 | −$1.37 | — | −$1.92 |